Tatva Chintan Pharma Chem: March ’22 Results Update
Moneylife Digital Team 28 April 2022
Tatva Chintan Pharma Chem (Tatva) reported another quarter of disappointing results. Revenue dropped by 9% y-o-y (year-on-year) and 6% q-o-q (quarter-on-quarter) to Rs99 crore as SDA (structure directing agent) revenue slipped by 28% sequentially on account of disruption in auto production due to chip shortage. The ongoing geo-political tension between Russia and Ukraine has further impacted...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
Already a subscriber ? Log in
Free Helpline
Legal Credit